Genetic Technologies Limited (ASX: GTG; Nasdaq: GENE), a diversified molecular diagnostics company. GTG offers cancer predictive testing and assessment tools to help physicians proactively manage patient health. The Company’s lead products GeneType for Breast Cancer and GeneType for Colorectal Cancer are clinically validated risk assessment tests and are first in class. Genetic Technologies is developing a pipeline of risk assessment products. Learn more at GENETechinfo.com.
The corporate presentation summarizes Aptorum Group Limited's portfolio of pharmaceutical and biotechnology projects, which include projects focused on orphan drug repurposing, infectious diseases, microbiome therapeutics, and dietary supplements. Key projects highlighted include ALS-4 for antibiotic resistant Staphylococcus aureus infections, CLS-1 targeting obesity via microbiome modulation, and NLS-2, a dietary supplement for menopausal symptoms. The presentation emphasizes Aptorum's progress advancing projects through development stages towards clinical trials and commercialization.
Genetic Technologies Limited (ASX: GTG; Nasdaq: GENE), a diversified molecular diagnostics company. GTG offers cancer predictive testing and assessment tools to help physicians proactively manage patient health. The Company’s lead products GeneType for Breast Cancer and GeneType for Colorectal Cancer are clinically validated risk assessment tests and are first in class. Genetic Technologies is developing a pipeline of risk assessment products. Learn more at GENETechinfo.com.
One in 8 U.S. women will develop invasive breast cancer over her lifetime, with approximately 266,000 new breast cancer patients and 3.1 million breast cancer survivors in 2018. Following breast cancer surgery in the adjuvant setting, a HER2/neu 3+ patient typically receives Herceptin® in the first year, with the hope that their breast cancer will not recur, and with the odds of recurrence slowly decreasing over the first 5 years after surgery. Herceptin® has been shown to reduce recurrence rates from 25% to 12% in the adjuvant setting. In the neoadjuvant setting, a patient receives treatment before surgery and based on the results of a biopsy at surgery, will receive the same or more potent treatment after surgery. Kadcyla® has been shown to reduce recurrence rates from 22% to 11% in the neoadjuvant setting. Accordingly, we believe that GP2 may be used to address the 50% of recurring patients who do not respond to either Herceptin® or Kadcyla®.
Gilead Sciences is a biopharmaceutical company headquartered in Foster City, California. It has a diverse portfolio of pharmaceutical products focused on HIV, hepatitis C, cardiovascular, and oncology. Gilead's key products include HIV drugs Atripla, Truvada, Complera, and Stribild, which accounted for over 40% of sales in 2015. Its hepatitis C drugs Sovaldi and Harvoni have been blockbuster successes, with Harvoni sales projected to reach $11.6 billion in 2015. Gilead has a strong pipeline and continues to invest heavily in research and development. It has significant cash flows and profit margins, with projected net income margins over 45% through 20
Genetic Technologies Limited (ASX: GTG; Nasdaq: GENE), a diversified molecular diagnostics company. GTG offers cancer predictive testing and assessment tools to help physicians proactively manage patient health. The Company’s lead products GeneType for Breast Cancer and GeneType for Colorectal Cancer are clinically validated risk assessment tests and are first in class. Genetic Technologies is developing a pipeline of risk assessment products. Learn more at GENETechinfo.com.
Cidara is developing long-acting therapeutics designed to improve the standard of care for patients facing serious diseases. The Company’s portfolio is comprised of drug candidates intended to transform existing treatment and prevention paradigms. Its lead Phase 3 antifungal candidate, rezafungin, will report Phase 3 data at the end of 2021. The potential peak sales opportunity for rezafungin in the US is ~$750M. In addition, the Company is developing Drug-Fc Conjugates (DFCs) targeting viral and oncology diseases from Cidara’s proprietary Cloudbreak® platform.
Cidara is developing long-acting therapeutics designed to improve the standard of care for patients facing serious diseases. The Company’s portfolio is comprised of drug candidates intended to transform existing treatment and prevention paradigms. Its lead Phase 3 antifungal candidate, rezafungin, will report Phase 3 data at the end of 2021. The potential peak sales opportunity for rezafungin in the US is ~$750M. In addition, the Company is developing Drug-Fc Conjugates (DFCs) targeting viral and oncology diseases from Cidara’s proprietary Cloudbreak® platform.
Ron Najafi, Chairman and CEO of NovaBay Pharmaceuticals, provided an update to shareholders at their annual meeting. NovaBay is developing new anti-infective products to address the growing crisis of antibiotic resistance. Their lead product candidates include auriclosene, which has shown effectiveness against bacteria, viruses, and fungi in clinical trials for conditions like conjunctivitis and impetigo, without inducing resistance. NovaBay also markets NeutroPhase, a pure hypochlorous acid solution for wound care. They anticipate results from multiple global phase 2 clinical trials in 2013 and have established partnerships to commercialize their products in key markets.
The corporate presentation summarizes Aptorum Group Limited's portfolio of pharmaceutical and biotechnology projects, which include projects focused on orphan drug repurposing, infectious diseases, microbiome therapeutics, and dietary supplements. Key projects highlighted include ALS-4 for antibiotic resistant Staphylococcus aureus infections, CLS-1 targeting obesity via microbiome modulation, and NLS-2, a dietary supplement for menopausal symptoms. The presentation emphasizes Aptorum's progress advancing projects through development stages towards clinical trials and commercialization.
Genetic Technologies Limited (ASX: GTG; Nasdaq: GENE), a diversified molecular diagnostics company. GTG offers cancer predictive testing and assessment tools to help physicians proactively manage patient health. The Company’s lead products GeneType for Breast Cancer and GeneType for Colorectal Cancer are clinically validated risk assessment tests and are first in class. Genetic Technologies is developing a pipeline of risk assessment products. Learn more at GENETechinfo.com.
One in 8 U.S. women will develop invasive breast cancer over her lifetime, with approximately 266,000 new breast cancer patients and 3.1 million breast cancer survivors in 2018. Following breast cancer surgery in the adjuvant setting, a HER2/neu 3+ patient typically receives Herceptin® in the first year, with the hope that their breast cancer will not recur, and with the odds of recurrence slowly decreasing over the first 5 years after surgery. Herceptin® has been shown to reduce recurrence rates from 25% to 12% in the adjuvant setting. In the neoadjuvant setting, a patient receives treatment before surgery and based on the results of a biopsy at surgery, will receive the same or more potent treatment after surgery. Kadcyla® has been shown to reduce recurrence rates from 22% to 11% in the neoadjuvant setting. Accordingly, we believe that GP2 may be used to address the 50% of recurring patients who do not respond to either Herceptin® or Kadcyla®.
Gilead Sciences is a biopharmaceutical company headquartered in Foster City, California. It has a diverse portfolio of pharmaceutical products focused on HIV, hepatitis C, cardiovascular, and oncology. Gilead's key products include HIV drugs Atripla, Truvada, Complera, and Stribild, which accounted for over 40% of sales in 2015. Its hepatitis C drugs Sovaldi and Harvoni have been blockbuster successes, with Harvoni sales projected to reach $11.6 billion in 2015. Gilead has a strong pipeline and continues to invest heavily in research and development. It has significant cash flows and profit margins, with projected net income margins over 45% through 20
Genetic Technologies Limited (ASX: GTG; Nasdaq: GENE), a diversified molecular diagnostics company. GTG offers cancer predictive testing and assessment tools to help physicians proactively manage patient health. The Company’s lead products GeneType for Breast Cancer and GeneType for Colorectal Cancer are clinically validated risk assessment tests and are first in class. Genetic Technologies is developing a pipeline of risk assessment products. Learn more at GENETechinfo.com.
Cidara is developing long-acting therapeutics designed to improve the standard of care for patients facing serious diseases. The Company’s portfolio is comprised of drug candidates intended to transform existing treatment and prevention paradigms. Its lead Phase 3 antifungal candidate, rezafungin, will report Phase 3 data at the end of 2021. The potential peak sales opportunity for rezafungin in the US is ~$750M. In addition, the Company is developing Drug-Fc Conjugates (DFCs) targeting viral and oncology diseases from Cidara’s proprietary Cloudbreak® platform.
Cidara is developing long-acting therapeutics designed to improve the standard of care for patients facing serious diseases. The Company’s portfolio is comprised of drug candidates intended to transform existing treatment and prevention paradigms. Its lead Phase 3 antifungal candidate, rezafungin, will report Phase 3 data at the end of 2021. The potential peak sales opportunity for rezafungin in the US is ~$750M. In addition, the Company is developing Drug-Fc Conjugates (DFCs) targeting viral and oncology diseases from Cidara’s proprietary Cloudbreak® platform.
Ron Najafi, Chairman and CEO of NovaBay Pharmaceuticals, provided an update to shareholders at their annual meeting. NovaBay is developing new anti-infective products to address the growing crisis of antibiotic resistance. Their lead product candidates include auriclosene, which has shown effectiveness against bacteria, viruses, and fungi in clinical trials for conditions like conjunctivitis and impetigo, without inducing resistance. NovaBay also markets NeutroPhase, a pure hypochlorous acid solution for wound care. They anticipate results from multiple global phase 2 clinical trials in 2013 and have established partnerships to commercialize their products in key markets.
This investor presentation by Cancer Genetics, Inc provides an overview of the company and its proprietary genomic testing programs. CGI has locations in the US, India, and China serving biopharma, clinical, and research clients. It has launched 7 proprietary diagnostic products focused on hematologic and urogenital cancers, and is working to validate additional next generation sequencing panels. CGI's tests provide information to aid in diagnosis, prognosis, and therapeutic decision making for cancers like CLL, cervical cancer, and kidney cancer. The company is collaborating with academic centers to further develop and validate its genomic tests.
Cancer Diagnostics Reference Laboratory / NeoGenomics April 2014 investors company overview presentation. This presentation highlights the following:
--Fast growing cancer genetics lab servicing Oncologists, Pathologists and Hostpitals
--Strategic client partnerships created by "Tech-Only" model
--Dynamic, rapidly-growing and consolidating industry
Industry-leading revenue & test volume growth
--Strong productivity and operating leverage leading to accelerating cash flow and net income
--Strong Management Team with large cap lab experience
Markntel Saudi Arabia Tumor Marker Market Analysis, 2020ShivaKumar1833
• The major growth factors for cancer biomarkers were increasing usage of biomarkers in cancer treatment in addition to R&D funding for pharma and biotech companies
• The distribution channel was smoothly steering growth as Saudi Arabia imports from Europe and conducted tests.
In this downloadable slideset, Joel E. Gallant, MD, MPH, and Anton L. Pozniak, MD, FRCP, review key studies presented at the 2015 ICAAC, IDWeek, and EACS meetings.
Format: Microsoft PowerPoint (.ppt)
File size: 2.64 MB
Date posted: 11/10/2015
Inovio Pharmaceuticals, Inc. - Revolutionizing the Fight Against Cancers and ...Company Spotlight
Dr. Joseph Kim, President and CEO of Inovio Pharmaceuticals, discusses Inovio's DNA immunotherapy products and clinical trial progress. Key points include:
1) Inovio's lead product, VGX-3100, met primary and secondary efficacy endpoints in a Phase II cervical dysplasia trial by regressing high-grade lesions and clearing HPV.
2) Phase III development of VGX-3100 for cervical dysplasia is underway, with initiation expected in 2016.
3) Inovio is also developing DNA immunotherapies for HPV-related cancers and expanding VGX-3100's application to additional HPV-associated diseases.
4)
NE3107 is a small molecule in Phase 3 clinical trials for Alzheimer's disease and Parkinson's disease. It works by inhibiting neuroinflammation and insulin resistance, two key drivers of cognitive decline. A Phase 3 trial for Alzheimer's is underway testing NE3107's ability to slow cognitive decline compared to placebo. Preclinical studies show NE3107 reduces inflammation, enhances insulin sensitivity, and has neuroprotective effects, supporting its potential in neurodegenerative diseases. A Phase 2 trial will assess NE3107's activity and safety when combined with L-dopa for Parkinson's disease.
One in 8 U.S. women will develop invasive breast cancer over her lifetime, with approximately 266,000 new breast cancer patients and 3.1 million breast cancer survivors in 2018. Following breast cancer surgery in the adjuvant setting, a HER2/neu 3+ patient typically receives Herceptin® in the first year, with the hope that their breast cancer will not recur, and with the odds of recurrence slowly decreasing over the first 5 years after surgery. Herceptin® has been shown to reduce recurrence rates from 25% to 12% in the adjuvant setting. In the neoadjuvant setting, a patient receives treatment before surgery and based on the results of a biopsy at surgery, will receive the same or more potent treatment after surgery. Kadcyla® has been shown to reduce recurrence rates from 22% to 11% in the neoadjuvant setting. Accordingly, we believe that GP2 may be used to address the 50% of recurring patients who do not respond to either Herceptin® or Kadcyla®.
IAS 2015.8th IAS Conference on HIV Pathogenesis, Treatment and Preventionhivlifeinfo
Highlights of IAS 2015
In this downloadable slideset, Andrew Carr, MBBS, MD, FRACP, FRCPA; Joel E. Gallant, MD, MPH; and Anton L. Pozniak, MD, FRCP, review key studies presented at the 2015 International AIDS Society conference.
Format: Microsoft PowerPoint (.ppt)
File size: 1.73 MB
The presentation discussed Protalix's plant cell-expressed, chemically modified human alpha-galactosidase for the treatment of Fabry disease, called PRX-102. Fabry disease is caused by a deficiency of the enzyme alpha-galactosidase A, leading to accumulation of Gb3 substrate and increased risks of stroke, cardiomyopathy, and renal issues. Currently available treatments have short half-lives. PRX-102 aims to be a "bio-better" enzyme by using chemical modification via covalent cross-linking of the subunits to create a stable dimer, which may provide advantages like improved stability, longer half-life, and enhanced uptake in target organs, potentially leading to better clinical efficacy than
Clinical Impact of Data From the CROI 2015,SeattleHivlife Info
This document summarizes key findings from the 2015 Conference on Retroviruses and Opportunistic Infections regarding HIV prevention and antiretroviral therapy. Studies presented showed that immediate use of PrEP reduced HIV risk by 86% compared to deferred use in high-risk MSM. On-demand PrEP also reduced risk by 86% in another study of MSM. Combining ART and PrEP in serodiscordant couples reduced expected infections by 96%. Regarding ART, tenofovir alafenamide fumarate was found to be noninferior to tenofovir disoproxil fumarate at week 48, with less impact on renal and bone safety markers.
1708 2 q presentation v6 uten back-upstargovax2017
This document provides a 3-sentence summary of a presentation by Targovax, a biotech company developing immunotherapies to treat cancer:
Targovax is developing two immunotherapy platforms, ONCOS-102 oncolytic virus and TG01 RAS peptide vaccine, to boost immune responses against cancer and has clinical trials ongoing or planned in several cancer types including pancreatic, melanoma, mesothelioma and others.
The presentation highlights interim clinical data from TG01 showing improved survival outcomes compared to historical controls in resected pancreatic cancer patients and outlines the company's clinical development plans and timelines over the next two years with multiple data readouts expected.
Targovax has sufficient cash runway into
This document outlines Bambang Budiono's presentation on COVID-19 vaccines. It discusses the body's natural immune response, how vaccines work to train the immune system, the development of different COVID-19 vaccines using various platforms, their efficacy rates in clinical trials, potential side effects, and who can safely receive the vaccines. The presentation covers cellular and humoral immunity against COVID-19, the parts of the virus best suited for vaccine development, how approved vaccines like Pfizer, Moderna, Oxford/AstraZeneca and Sinovac function, and considerations around long term protection.
Kiromic BioPharma, Inc. is a target discovery and gene-editing company utilizing artificial intelligence and its proprietary neural network platform with a therapeutic focus on immuno-oncology.
Targovax is developing two cancer immunotherapy drugs - ONCOS-102, an oncolytic virus, and TG01, a neoantigen vaccine. Data from clinical trials of ONCOS-102 showed it activated patients' immune systems against their tumors. Targovax has an ongoing clinical program testing ONCOS-102 in various cancer types and combinations. TG01 targets RAS mutations in pancreatic cancer and showed encouraging long-term survival rates in previous trials. A recent trial combining TG01 with chemotherapy showed improved median and 2-year survival over historical controls. Targovax is seeking a partner to advance TG01 into a late-stage trial aimed at registration.
This document provides an overview of Cancer Genetics, Inc. It discusses the company's focus on empowering personalized cancer treatment through molecular diagnostics. The summary highlights Cancer Genetics' proprietary diagnostic products for various cancers, partnerships with biopharma companies, growth in revenue and testing volume in 2013, and pipeline of diagnostic tests in development. It also outlines the company's business model and strategy to commercialize its products to target markets globally.
1706 ir deck full w_appendix v1_cmd_v6_uten appendixtargovax2017
The document summarizes a capital markets update presentation by Targovax. It discusses Targovax's two immunotherapy platforms - ONCOS-102, an oncolytic virus, and TG01, a peptide cancer vaccine. For ONCOS-102, the virus is injected into tumors where it stimulates an immune response by releasing cancer antigens. TG01 mimics antigens to stimulate "killer" T-cells. Early clinical trial results for ONCOS-102 showed increased tumor-infiltrating T-cells and systemic immune responses in cancer patients. Targovax is pursuing multiple clinical trials to combine its immunotherapies with other treatments.
"Global HIV Vaccine Market Future Outlook" Report Highlights:
Introduction to HIV Vaccines
Issues Related to the Development of HIV Vaccines
Parameters for Successful Commercialization of HIV Vaccines
Global HIV Vaccines Market Opportunity Analysis
Global HIV Vaccine Clinical Pipeline by Company & Phase
Global HIV Vaccine Clinical Pipeline: 100 Vaccines
Majority Vaccine in Preclinical Phase: 42 Vaccines
Targovax presented highlights from Q1 2017, including encouraging survival data from a phase I/II trial of TG01 in pancreatic cancer. 68% of patients were still alive after 2 years, compared to historical rates of 30-53%. Targovax will present further clinical data on TG01 at ASCO in June. The company initiated an exploratory trial of TG01 in colorectal cancer and has six clinical trials ongoing or planned in 2017-2018 across cancer indications. Financially, Targovax has cash of NOK 147M and an operating expenses run rate of NOK 104M annually based on the last four quarters.
This document provides an overview of Targovax, a biotechnology company developing immunotherapy treatments for cancer. It summarizes Targovax's two platform technologies: ONCOS-102, an oncolytic virus that selectively infects and lyses cancer cells to trigger an immune response, and TG neoantigen vaccines that target specific cancer mutations to generate T-cells to kill cancer cells. The document outlines Targovax's clinical development plans and timelines across six clinical trials in several cancer indications. It also reviews the company's financial position and shareholder base, noting a strong cash runway into 2019 to complete the planned clinical program.
The document provides an overview of Genetic Technologies Company (GTG), including:
- GTG is developing genetic risk assessment products to prevent disease morbidity and mortality.
- GTG has 20 years experience commercializing genomics products and research partnerships with universities and companies.
- GTG's flagship product BREVAGenplus predicts a woman's risk of developing breast cancer using a cheek swab and has been clinically validated in multiple populations.
Genetic Technologies Limited (ASX: GTG; Nasdaq: GENE), a diversified molecular diagnostics company. GTG offers cancer predictive testing and assessment tools to help physicians proactively manage patient health. The Company’s lead products GeneType for Breast Cancer and GeneType for Colorectal Cancer are clinically validated risk assessment tests and are first in class. Genetic Technologies is developing a pipeline of risk assessment products. Learn more at GENETechinfo.com.
This investor presentation by Cancer Genetics, Inc provides an overview of the company and its proprietary genomic testing programs. CGI has locations in the US, India, and China serving biopharma, clinical, and research clients. It has launched 7 proprietary diagnostic products focused on hematologic and urogenital cancers, and is working to validate additional next generation sequencing panels. CGI's tests provide information to aid in diagnosis, prognosis, and therapeutic decision making for cancers like CLL, cervical cancer, and kidney cancer. The company is collaborating with academic centers to further develop and validate its genomic tests.
Cancer Diagnostics Reference Laboratory / NeoGenomics April 2014 investors company overview presentation. This presentation highlights the following:
--Fast growing cancer genetics lab servicing Oncologists, Pathologists and Hostpitals
--Strategic client partnerships created by "Tech-Only" model
--Dynamic, rapidly-growing and consolidating industry
Industry-leading revenue & test volume growth
--Strong productivity and operating leverage leading to accelerating cash flow and net income
--Strong Management Team with large cap lab experience
Markntel Saudi Arabia Tumor Marker Market Analysis, 2020ShivaKumar1833
• The major growth factors for cancer biomarkers were increasing usage of biomarkers in cancer treatment in addition to R&D funding for pharma and biotech companies
• The distribution channel was smoothly steering growth as Saudi Arabia imports from Europe and conducted tests.
In this downloadable slideset, Joel E. Gallant, MD, MPH, and Anton L. Pozniak, MD, FRCP, review key studies presented at the 2015 ICAAC, IDWeek, and EACS meetings.
Format: Microsoft PowerPoint (.ppt)
File size: 2.64 MB
Date posted: 11/10/2015
Inovio Pharmaceuticals, Inc. - Revolutionizing the Fight Against Cancers and ...Company Spotlight
Dr. Joseph Kim, President and CEO of Inovio Pharmaceuticals, discusses Inovio's DNA immunotherapy products and clinical trial progress. Key points include:
1) Inovio's lead product, VGX-3100, met primary and secondary efficacy endpoints in a Phase II cervical dysplasia trial by regressing high-grade lesions and clearing HPV.
2) Phase III development of VGX-3100 for cervical dysplasia is underway, with initiation expected in 2016.
3) Inovio is also developing DNA immunotherapies for HPV-related cancers and expanding VGX-3100's application to additional HPV-associated diseases.
4)
NE3107 is a small molecule in Phase 3 clinical trials for Alzheimer's disease and Parkinson's disease. It works by inhibiting neuroinflammation and insulin resistance, two key drivers of cognitive decline. A Phase 3 trial for Alzheimer's is underway testing NE3107's ability to slow cognitive decline compared to placebo. Preclinical studies show NE3107 reduces inflammation, enhances insulin sensitivity, and has neuroprotective effects, supporting its potential in neurodegenerative diseases. A Phase 2 trial will assess NE3107's activity and safety when combined with L-dopa for Parkinson's disease.
One in 8 U.S. women will develop invasive breast cancer over her lifetime, with approximately 266,000 new breast cancer patients and 3.1 million breast cancer survivors in 2018. Following breast cancer surgery in the adjuvant setting, a HER2/neu 3+ patient typically receives Herceptin® in the first year, with the hope that their breast cancer will not recur, and with the odds of recurrence slowly decreasing over the first 5 years after surgery. Herceptin® has been shown to reduce recurrence rates from 25% to 12% in the adjuvant setting. In the neoadjuvant setting, a patient receives treatment before surgery and based on the results of a biopsy at surgery, will receive the same or more potent treatment after surgery. Kadcyla® has been shown to reduce recurrence rates from 22% to 11% in the neoadjuvant setting. Accordingly, we believe that GP2 may be used to address the 50% of recurring patients who do not respond to either Herceptin® or Kadcyla®.
IAS 2015.8th IAS Conference on HIV Pathogenesis, Treatment and Preventionhivlifeinfo
Highlights of IAS 2015
In this downloadable slideset, Andrew Carr, MBBS, MD, FRACP, FRCPA; Joel E. Gallant, MD, MPH; and Anton L. Pozniak, MD, FRCP, review key studies presented at the 2015 International AIDS Society conference.
Format: Microsoft PowerPoint (.ppt)
File size: 1.73 MB
The presentation discussed Protalix's plant cell-expressed, chemically modified human alpha-galactosidase for the treatment of Fabry disease, called PRX-102. Fabry disease is caused by a deficiency of the enzyme alpha-galactosidase A, leading to accumulation of Gb3 substrate and increased risks of stroke, cardiomyopathy, and renal issues. Currently available treatments have short half-lives. PRX-102 aims to be a "bio-better" enzyme by using chemical modification via covalent cross-linking of the subunits to create a stable dimer, which may provide advantages like improved stability, longer half-life, and enhanced uptake in target organs, potentially leading to better clinical efficacy than
Clinical Impact of Data From the CROI 2015,SeattleHivlife Info
This document summarizes key findings from the 2015 Conference on Retroviruses and Opportunistic Infections regarding HIV prevention and antiretroviral therapy. Studies presented showed that immediate use of PrEP reduced HIV risk by 86% compared to deferred use in high-risk MSM. On-demand PrEP also reduced risk by 86% in another study of MSM. Combining ART and PrEP in serodiscordant couples reduced expected infections by 96%. Regarding ART, tenofovir alafenamide fumarate was found to be noninferior to tenofovir disoproxil fumarate at week 48, with less impact on renal and bone safety markers.
1708 2 q presentation v6 uten back-upstargovax2017
This document provides a 3-sentence summary of a presentation by Targovax, a biotech company developing immunotherapies to treat cancer:
Targovax is developing two immunotherapy platforms, ONCOS-102 oncolytic virus and TG01 RAS peptide vaccine, to boost immune responses against cancer and has clinical trials ongoing or planned in several cancer types including pancreatic, melanoma, mesothelioma and others.
The presentation highlights interim clinical data from TG01 showing improved survival outcomes compared to historical controls in resected pancreatic cancer patients and outlines the company's clinical development plans and timelines over the next two years with multiple data readouts expected.
Targovax has sufficient cash runway into
This document outlines Bambang Budiono's presentation on COVID-19 vaccines. It discusses the body's natural immune response, how vaccines work to train the immune system, the development of different COVID-19 vaccines using various platforms, their efficacy rates in clinical trials, potential side effects, and who can safely receive the vaccines. The presentation covers cellular and humoral immunity against COVID-19, the parts of the virus best suited for vaccine development, how approved vaccines like Pfizer, Moderna, Oxford/AstraZeneca and Sinovac function, and considerations around long term protection.
Kiromic BioPharma, Inc. is a target discovery and gene-editing company utilizing artificial intelligence and its proprietary neural network platform with a therapeutic focus on immuno-oncology.
Targovax is developing two cancer immunotherapy drugs - ONCOS-102, an oncolytic virus, and TG01, a neoantigen vaccine. Data from clinical trials of ONCOS-102 showed it activated patients' immune systems against their tumors. Targovax has an ongoing clinical program testing ONCOS-102 in various cancer types and combinations. TG01 targets RAS mutations in pancreatic cancer and showed encouraging long-term survival rates in previous trials. A recent trial combining TG01 with chemotherapy showed improved median and 2-year survival over historical controls. Targovax is seeking a partner to advance TG01 into a late-stage trial aimed at registration.
This document provides an overview of Cancer Genetics, Inc. It discusses the company's focus on empowering personalized cancer treatment through molecular diagnostics. The summary highlights Cancer Genetics' proprietary diagnostic products for various cancers, partnerships with biopharma companies, growth in revenue and testing volume in 2013, and pipeline of diagnostic tests in development. It also outlines the company's business model and strategy to commercialize its products to target markets globally.
1706 ir deck full w_appendix v1_cmd_v6_uten appendixtargovax2017
The document summarizes a capital markets update presentation by Targovax. It discusses Targovax's two immunotherapy platforms - ONCOS-102, an oncolytic virus, and TG01, a peptide cancer vaccine. For ONCOS-102, the virus is injected into tumors where it stimulates an immune response by releasing cancer antigens. TG01 mimics antigens to stimulate "killer" T-cells. Early clinical trial results for ONCOS-102 showed increased tumor-infiltrating T-cells and systemic immune responses in cancer patients. Targovax is pursuing multiple clinical trials to combine its immunotherapies with other treatments.
"Global HIV Vaccine Market Future Outlook" Report Highlights:
Introduction to HIV Vaccines
Issues Related to the Development of HIV Vaccines
Parameters for Successful Commercialization of HIV Vaccines
Global HIV Vaccines Market Opportunity Analysis
Global HIV Vaccine Clinical Pipeline by Company & Phase
Global HIV Vaccine Clinical Pipeline: 100 Vaccines
Majority Vaccine in Preclinical Phase: 42 Vaccines
Targovax presented highlights from Q1 2017, including encouraging survival data from a phase I/II trial of TG01 in pancreatic cancer. 68% of patients were still alive after 2 years, compared to historical rates of 30-53%. Targovax will present further clinical data on TG01 at ASCO in June. The company initiated an exploratory trial of TG01 in colorectal cancer and has six clinical trials ongoing or planned in 2017-2018 across cancer indications. Financially, Targovax has cash of NOK 147M and an operating expenses run rate of NOK 104M annually based on the last four quarters.
This document provides an overview of Targovax, a biotechnology company developing immunotherapy treatments for cancer. It summarizes Targovax's two platform technologies: ONCOS-102, an oncolytic virus that selectively infects and lyses cancer cells to trigger an immune response, and TG neoantigen vaccines that target specific cancer mutations to generate T-cells to kill cancer cells. The document outlines Targovax's clinical development plans and timelines across six clinical trials in several cancer indications. It also reviews the company's financial position and shareholder base, noting a strong cash runway into 2019 to complete the planned clinical program.
The document provides an overview of Genetic Technologies Company (GTG), including:
- GTG is developing genetic risk assessment products to prevent disease morbidity and mortality.
- GTG has 20 years experience commercializing genomics products and research partnerships with universities and companies.
- GTG's flagship product BREVAGenplus predicts a woman's risk of developing breast cancer using a cheek swab and has been clinically validated in multiple populations.
Genetic Technologies Limited (ASX: GTG; Nasdaq: GENE), a diversified molecular diagnostics company. GTG offers cancer predictive testing and assessment tools to help physicians proactively manage patient health. The Company’s lead products GeneType for Breast Cancer and GeneType for Colorectal Cancer are clinically validated risk assessment tests and are first in class. Genetic Technologies is developing a pipeline of risk assessment products. Learn more at GENETechinfo.com.
- IDXG provides molecular diagnostic tests for cancer risk assessment and prognosis.
- Recent accomplishments include new product launches, reimbursement from Aetna for ThyraMir, and achieving approval in New York State.
- The presentation provides financial information, with revenue growing but losses continuing from investments in sales, R&D and administrative expenses.
Genetic Technologies is a diversified molecular diagnostics company. A global leader in genomics-based tests in health, wellness and serious disease through its geneType and EasyDNA brands. GENE offers cancer predictive testing and assessment tools to help physicians to improve health outcomes for people around the world. The Company has a proprietary risk stratification platform that has been developed over the past decade and integrates clinical and genetic risk to deliver actionable outcomes to physicians and individuals. Leading the world in risk prediction in oncology, cardiovascular and metabolic diseases, Genetic Technologies continues to develop risk assessment products.
Genetic Technologies is a diversified molecular diagnostics company. A global leader in genomics-based tests in health, wellness and serious disease through its geneType and EasyDNA brands. GENE offers cancer predictive testing and assessment tools to help physicians to improve health outcomes for people around the world. The Company has a proprietary risk stratification platform that has been developed over the past decade and integrates clinical and genetic risk to deliver actionable outcomes to physicians and individuals. Leading the world in risk prediction in oncology, cardiovascular and metabolic diseases, Genetic Technologies continues to develop risk assessment products.
Genetic Technologies Limited is a diversified molecular diagnostics
company developing tools for the prediction and assessment of cancer
risk to help physicians proactively manage patient health. The
Company’s lead products, ‘GeneType for Breast Cancer’ and
‘GeneType for Colorectal Cancer’, are clinically validated risk
assessment tests that are first in their class. The Company’s
development pipeline includes new tests for COVID-19, Type 2
diabetes, cardiovascular disease, prostate cancer, and melanoma.
Listed on the ASX in 2000 and NASDAQ in 2005, Genetic
Technologies has been a leader in the development and
commercialization of genetic risk assessment technology for 20 years.
This document discusses principles of cancer screening and summarizes a proposed cancer screening program called CitiScreen. It begins by outlining the Wilson-Jungner criteria for cancer screening approved by the WHO. It then discusses updated screening criteria and reviews the scientific basis for cancer screening through randomized controlled trials and other methods. The document summarizes CitiScreen's goal of comprehensive cancer screening through a combination of technologies and outlines screening patterns for specific cancers like breast, ovarian, lung, and colorectal cancer.
Microbiome Diagnostics Platform for Microbiome Health and Colon Cancer Preven...Laura Berry
Presented at the 4th Microbiome R&D and Business Collaboration Forum: USA. To find out more, visit: www.global-engage.com
Greg Kuehn, President and COO of Metabiomics, presents the MB-01 colorectal adenoma clinical research study, sequencing technology and microbiome diagnostics platform.
Genetic Technologies Limited is a diversified molecular diagnostics company
developing tools for the prediction and assessment of cancer risk to help physicians
proactively manage patient health. The Company’s lead products, ‘GeneType for
Breast Cancer’ and ‘GeneType for Colorectal Cancer’, are clinically validated risk
assessment tests that are first in their class. The Company’s development pipeline
includes new tests for Type 2 diabetes, cardiovascular disease, prostate cancer, and
melanoma. Listed on the ASX in 2000 and NASDAQ in 2005, Genetic Technologies
has been a leader in the development and commercialization of genetic risk
assessment technology for 20 years.
Breast cancer is the most common cancer in women. Rates are higher in Black women than White women due to disparities in screening and treatment. Genetic and lifestyle factors affect risk, and regular screening is recommended starting at age 40. However, some groups face barriers to screening like lack of access to care, knowledge, and cultural beliefs. Researchers are working to better understand risk factors and improve prevention and individualized treatment through studies on genetics, screening methods, and high-risk populations.
Cancer Genetics provides personalized cancer treatment through molecular diagnostic testing. They have launched 6 proprietary diagnostic products targeting hematological and urogenital cancers. Their tests help determine cancer type and prognosis, guiding treatment selection. Recent acquisitions expand their capabilities and access to new markets in India. Their business model provides clinical testing services to oncologists and biopharma partnerships to support drug development.
1. Early detection of cancer is important for effective treatment and reducing cancer deaths. When cancer is detected earlier, treatment works better and is less complex.
2. There are barriers to early detection like lack of awareness, access to care, and follow up. Building capacity for early diagnosis through education, accessible services, and coordinated care can help address these barriers.
3. A strategic, integrated approach is needed to strengthen early diagnosis including improving primary care evaluation and diagnostic testing, as well as ensuring timely access to treatment.
Genetic Alliance UK aims to improve lives affected by genetic conditions. Nick Meade discusses preimplantation genetic diagnosis (PGD), which enables couples at high risk of passing on genetic conditions to screen embryos and transfer only unaffected ones. He explains that PGD requires clinical eligibility, funding approval, and the condition to be deemed serious by regulators. Access also depends on regulatory and financial criteria. Areas of ongoing discussion include what conditions qualify and regulating PGD's use.
DiaGenomi Ltd. is a genetic testing company that offers several tests through their MyRISQ platform, including CardioRISQ. CardioRISQ is a cardiac risk assessment test that combines genetic testing for mutations in several genes related to cardiovascular disease with a lifestyle questionnaire. It provides a personalized assessment of cardiovascular disease risk. The test involves collecting a saliva sample for genetic analysis, completing an online lifestyle questionnaire, and receiving a medical report integrating this genetic and lifestyle data to provide a risk assessment and treatment plan tailored to the individual. DiaGenomi aims to improve prevention and management of disease through this holistic, personalized approach to genetic testing.
Similar to Genetic Technologies Biotech Showcase Presentation (20)
Based in Ann Arbor, Michigan, Zomedica is a veterinary health company creating diagnostic and therapeutic products for horses, dogs, and cats by focusing on the unmet needs of clinical veterinarians. With modest cash burn and a strong balance sheet, including $142.4 million cash and cash equivalents as of June 30, 2023, Zomedica is well-positioned to fund both organic growth and acquisitions.
Docola has developed a healthcare communication platform that utilizes asynchronous telehealth to deliver patient education and support. Their proprietary platform currently has over 55,000 patient users and over 1,100 clinician users. Docola seeks to raise up to $500,000 through a convertible note to fund working capital, research and development, and costs associated with an upcoming IPO.
- INNO Holdings is presenting an IPO investor presentation for an initial public offering on the NASDAQ Capital Market.
- The company manufactures prefabricated steel building components and systems using proprietary technology to reduce construction costs and environmental impact.
- INNO Holdings has four initial product lines - metal studs, prefabricated housing units, modular apartment buildings, and a mobile factory system. It aims to disrupt the construction industry through standardized, sustainable construction methods.
Everything Blockchain builds platforms of trust for the modern enterprise and is on a mission to ensure every organization has access to the tools and platforms that enable them to manage, store, and protect data without the cost and complexity that holds them back today. The Company’s patented advances in engineering deliver the essential elements needed for real-world business use: speed, security, and efficiency. Everything Blockchain’s current business lines include: EB Advise, Build DB and EB Control.
ASP Isotope is an isotope enrichment company utilizing technology developed in South Africa over the past 20 years to enrich isotopes of elements or molecules with low atomic masses. Many of these elements are unsuitable for enrichment using traditional methods such as centrifuges. The Company’s initial focus is on producing and commercializing highly enriched isotopes for the healthcare and technology industries.
MDNA Life Sciences is a pioneer in the science of mitochondrial DNA. It’s our mission to create an extensive portfolio of proprietary tests that dramatically improve diagnosis, treatment, prognosis and monitoring. Putting an end to the unnecessary surgical procedures, pain and uncertainty that affect patients across the world.
Digital Ally, Inc. is a diversified holding company with operations in video solution technology, human and animal health protection products, healthcare revenue cycle management, ticket brokering and marketing, and event production. The Company pursues an acquisition strategy that targets organizations with positive earnings, strong growth potential, innovation, and operational synergies. To maximize long-term shareholder value, Digital Ally intends to spin-off its ticketing and entertainment business lines into a separate public company in 2023. The spin-off will create two optimized, tech-driven public companies with strong growth opportunities and operating metrics.
Lantern Pharma is an AI company transforming the cost, pace, and timeline of oncology drug discovery and development. Our proprietary AI and machine learning (ML) platform, RADR®, leverages over 25 billion oncology-focused data points and a library of 200+ advanced ML algorithms to help solve billion-dollar, real-world problems in oncology drug development. By harnessing the power of AI and with input from world-class scientific advisors and collaborators, we have accelerated the development of our growing pipeline of therapies including eleven cancer indications and an antibody-drug conjugate (ADC) program. On average, our newly developed drug programs have been advanced from initial AI insights to first-in-human clinical trials in 2-3 years and at approximately $1.0-2.0 million per program.
Sharps Technology is a medical device and pharmaceutical packaging company specializing in the development and manufacturing of innovative drug delivery systems. The Company’s product lines focus on low waste and ultra-low waste syringe technologies that incorporate both passive and active safety features. These features protect front line healthcare workers from life-threatening needle stick injuries and protect the public from needle re-use. Sharps Technology has extensive expertise in specialized prefilled syringe systems and is on track to launch this new product line in Q4 2023. The Company has a manufacturing facility in Hungary and has partnered with Nephron Pharmaceuticals to expand its manufacturing capacity in the US.
Aditxt is a biotech company developing immune monitoring and immune modulation platforms. Its AditxtScore platform can provide comprehensive immune profiles to monitor responses to pathogens, vaccines, drugs and transplants. Its Adimune platform aims to modulate the immune system to treat conditions like psoriasis, type 1 diabetes, and increase skin allograft survival. The company is working to develop, operate and commercialize these platforms. It currently generates revenue from immune monitoring tests and expects revenue from licensing deals for immune modulation programs as they advance in clinical trials towards commercialization.
1847 Holdings LLC, a publicly traded diversified acquisition holding company, was founded by Ellery W. Roberts, a former partner of Parallel Investment Partners, Saunders Karp & Megrue and Principal of Lazard Freres Strategic Realty Investors. EFSH's investment thesis is that capital market inefficiencies have left the founders and/or stakeholders of many small business enterprises and lower-middle market businesses with limited exit options, despite the intrinsic value of their business. Given this dynamic, EFSH can consistently acquire "solid" businesses for reasonable multiples of cash flow and then deploy resources to strengthen the infrastructure and systems to improve operations. These improvements may lead to a sale or IPO of an operating subsidiary at considerably higher valuations than the purchase price (as successfully demonstrated with the mid-2020 IPO of 1847 Goedeker on the NYSE American) and/or alternatively, an operating subsidiary may be held in perpetuity and contribute to EFSH's ability to pay regular and special dividends to shareholders.
Sharps Technology is a medical device and pharmaceutical packaging company specializing in the development and manufacturing of innovative drug delivery systems. The Company’s product lines focus on low waste and ultra-low waste syringe technologies that incorporate both passive and active safety features. These features protect front line healthcare workers from life-threatening needle stick injuries and protect the public from needle re-use. Sharps Technology has extensive expertise in specialized prefilled syringe systems and is on track to launch this new product line in Q4 2023. The Company has a manufacturing facility in Hungary and has partnered with Nephron Pharmaceuticals to expand its manufacturing capacity in the US.
SPI Energy is a global renewable energy company and provider of solar storage and electric vehicle (EV) solutions that was founded in 2006 in Roseville, California and is headquartered in McClellan Park, California. The Company has three core divisions: SolarJuice which has solar wholesale distribution, as well as residential solar and roofing installation and solar module manufacturing (Solar4America & SEM Wafertech), SPI Solar and Orange Power which operates a commercial & utility solar division, and the EdisonFuture/Phoenix Motor EV division. SolarJuice is the leader in renewable energy system solutions for residential and small commercial markets and has extensive operations in the Asia Pacific and North America markets. The SPI Solar commercial & utility solar division provides a full spectrum of EPC services to third party project developers, and develops, owns and operates solar projects that sell electricity to the grid in multiple regions, including the U.S., U.K., and Europe. Phoenix Motor is a leader in medium-duty commercial electric vehicles, and is developing EV charger solutions, electric pickup trucks, electric forklifts, and other EV products. SPI maintains global operations in North America, Australia, Asia and Europe and is also targeting strategic investment opportunities in fast growing green energy industries such as battery storage, charging stations, and other EVs which leverage the Company's expertise and substantial solar cash flow.
BullFrog AI is a technology enabled drug development company using machine learning to usher in a new era of precision medicine. Through its collaborations with leading research institutions, including Johns Hopkins University and J. Craig Venter Institute, BullFrog AI is at the forefront of AI-driven drug development. Using its proprietary bfLEAP™ artificial intelligence platform, BullFrog AI aims to enable the successful development of pharmaceuticals and biologics by predicting which patients will respond to therapies in development. BullFrog AI is deploying bfLEAP™ for use at several critical stages of development with the intention of streamlining data analytics in therapeutics development, decreasing the overall development costs by decreasing failure rates for new therapeutics, and impacting the lives of countless patients that may have otherwise not received the therapies they need.
BullFrog AI is a technology enabled drug development company using machine learning to usher in a new era of precision medicine. Through its collaborations with leading research institutions, including Johns Hopkins University and J. Craig Venter Institute, BullFrog AI is at the forefront of AI-driven drug development. Using its proprietary bfLEAP™ artificial intelligence platform, BullFrog AI aims to enable the successful development of pharmaceuticals and biologics by predicting which patients will respond to therapies in development. BullFrog AI is deploying bfLEAP™ for use at several critical stages of development with the intention of streamlining data analytics in therapeutics development, decreasing the overall development costs by decreasing failure rates for new therapeutics, and impacting the lives of countless patients that may have otherwise not received the therapies they need.
BioVie is a clinical-stage company developing what it believes will be transformative therapies to overcome unmet medical needs in neurodegeneration and liver disease. The Company is developing NE3107 for Alzheimer’s (AD) and Parkinson’s (PD) and BIV201 for refractory ascites and HRS-AKI.
Lantern Pharma is an AI company transforming the cost, pace, and timeline of oncology drug discovery and development. Our proprietary AI and machine learning (ML) platform, RADR®, leverages over 25 billion oncology-focused data points and a library of 200+ advanced ML algorithms to help solve billion-dollar, real-world problems in oncology drug development. By harnessing the power of AI and with input from world-class scientific advisors and collaborators, we have accelerated the development of our growing pipeline of therapies including eleven cancer indications and an antibody-drug conjugate (ADC) program. On average, our newly developed drug programs have been advanced from initial AI insights to first-in-human clinical trials in 2-3 years and at approximately $1.0-2.0 million per program.
Genetic Technologies is a diversified molecular diagnostics company. A global leader in genomics-based tests in health, wellness and serious disease through its geneType and EasyDNA brands. GENE offers cancer predictive testing and assessment tools to help physicians to improve health outcomes for people around the world. The Company has a proprietary risk stratification platform that has been developed over the past decade and integrates clinical and genetic risk to deliver actionable outcomes to physicians and individuals. Leading the world in risk prediction in oncology, cardiovascular and metabolic diseases, Genetic Technologies continues to develop risk assessment products.
Splash Beverage Group, an innovator in the beverage industry, owns a growing portfolio of alcoholic and non-alcoholic beverage brands including Copa di Vino wines by the glass, SALT naturally flavored tequilas, Pulpoloco Sangria, and TapouT performance hydration and recovery drinks and TapouT Cognitive Energy Drink. Splash’s strategy is to rapidly develop early-stage brands already in its portfolio as well as acquire and then accelerate brands that have high visibility or are innovators in their categories. Led by a management team that has built and managed some of the top brands in the beverage industry and led sales from product launch into the billions, Splash is rapidly expanding its brand portfolio and global distribution.
Splash Beverage Group, an innovator in the beverage industry, owns a growing portfolio of alcoholic and non-alcoholic beverage brands including Copa di Vino wines by the glass, SALT naturally flavored tequilas, Pulpoloco Sangria, and TapouT performance hydration and recovery drinks and TapouT Cognitive Energy Drink. Splash’s strategy is to rapidly develop early-stage brands already in its portfolio as well as acquire and then accelerate brands that have high visibility or are innovators in their categories. Led by a management team that has built and managed some of the top brands in the beverage industry and led sales from product launch into the billions, Splash is rapidly expanding its brand portfolio and global distribution.
Research, Monitoring and Evaluation, in Public Healthaghedogodday
This is a presentation on the overview of the role of monitoring and evaluation in public health. It describes the various components and how a robust M&E system can possitively impact the results or effectiveness of a public health intervention.
At Malayali Kerala Spa Ajman, Full Service includes individualized care for every client. We specifically design each massage session for the individual needs of the client. Our therapists are always willing to adjust the treatments based on the client's instruction and feedback. This guarantees that every client receives the treatment they expect.
By offering a variety of massage services, our Ajman Spa Massage Center can tackle physical, mental, and emotional illnesses. In addition, efficient identification of specific health conditions and designing treatment plans accordingly can significantly enhance the quality of massaging.
At Malayali Kerala Spa Ajman, we firmly believe that everyone should have the option to experience top-quality massage services regularly. To achieve that goal we offer cheap massage services in Ajman.
If you are interested in experiencing transformative massage treatment at Malayali Kerala Spa Ajman, you can use our Ajman Massage Center WhatsApp Number to schedule your next massage session.
Contact @ +971 529818279
Visit @ https://malayalikeralaspaajman.com/
Cancer treatment has advanced significantly over the years, offering patients various options tailored to their specific type of cancer and stage of disease. Understanding the different types of cancer treatments can help patients make informed decisions about their care. In this ppt, we have listed most common forms of cancer treatment available today.
Malayali Kerala Spa in Ajman, one among the top rated massage centre in ajman, welcomes you to experience high quality massage services from massage staffs from all ove rthe world! Being the best spa massage service providers, we take pride in offering traditional massage services of different countries, like
Indian Massage, Kerala Massage, Thai Massage, Pakistani Massage, Russian Massage etc
If you are seeking relaxation, pain relief, or wellness experience, our ajman spa is here for your unique needs and concerns. The services of our experienced therapists, and personalized attention will ensure that each visit will be memorable for you.
Book your appointment today and let us take you to a world of serenity and self-care. Because you deserves the best.
Digital Health in India_Health Informatics Trained Manpower _DrDevTaneja_15.0...DrDevTaneja1
Digital India will need a big trained army of Health Informatics educated & trained manpower in India.
Presently, generalist IT manpower does most of the work in the healthcare industry in India. Academic Health Informatics education is not readily available at school & health university level or IT education institutions in India.
We look into the evolution of health informatics and its applications in the healthcare industry.
HIMMS TIGER resources are available to assist Health Informatics education.
Indian Health universities, IT Education institutions, and the healthcare industry must proactively collaborate to start health informatics courses on a big scale. An advocacy push from various stakeholders is also needed for this goal.
Health informatics has huge employment potential and provides a big business opportunity for the healthcare industry. A big pool of trained health informatics manpower can lead to product & service innovations on a global scale in India.
2024 Media Preferences of Older Adults: Consumer Survey and Marketing Implica...Media Logic
When it comes to creating marketing strategies that target older adults, it is crucial to have insight into their media habits and preferences. Understanding how older adults consume and use media is key to creating acquisition and retention strategies. We recently conducted our seventh annual survey to gain insight into the media preferences of older adults in 2024. Here are the survey responses and marketing implications that stood out to us.
Health Tech Market Intelligence Prelim Questions -Gokul Rangarajan
The Ultimate Guide to Setting up Market Research in Health Tech part -1
How to effectively start market research in the health tech industry by defining objectives, crafting problem statements, selecting methods, identifying data collection sources, and setting clear timelines. This guide covers all the preliminary steps needed to lay a strong foundation for your research.
This lays foundation of scoping research project what are the
Before embarking on a research project, especially one aimed at scoping and defining parameters like the one described for health tech IT, several crucial considerations should be addressed. Here’s a comprehensive guide covering key aspects to ensure a well-structured and successful research initiative:
1. Define Research Objectives and Scope
Clear Objectives: Define specific goals such as understanding market needs, identifying new opportunities, assessing risks, or refining pricing strategies.
Scope Definition: Clearly outline the boundaries of the research in terms of geographical focus, target demographics (e.g., age, socio-economic status), and industry sectors (e.g., healthcare IT).
3. Review Existing Literature and Resources
Literature Review: Conduct a thorough review of existing research, market reports, and relevant literature to build foundational knowledge.
Gap Analysis: Identify gaps in existing knowledge or areas where further exploration is needed.
4. Select Research Methodology and Tools
Methodological Approach: Choose appropriate research methods such as surveys, interviews, focus groups, or data analytics.
Tools and Resources: Select tools like Google Forms for surveys, analytics platforms (e.g., SimilarWeb, Statista), and expert consultations.
5. Ethical Considerations and Compliance
Ethical Approval: Ensure compliance with ethical guidelines for research involving human subjects.
Data Privacy: Implement measures to protect participant confidentiality and adhere to data protection regulations (e.g., GDPR, HIPAA).
6. Budget and Resource Allocation
Resource Planning: Allocate resources including time, budget, and personnel required for each phase of the research.
Contingency Planning: Anticipate and plan for unforeseen challenges or adjustments to the research plan.
7. Develop Research Instruments
Survey Design: Create well-structured surveys using tools like Google Forms to gather quantitative data.
Interview and Focus Group Guides: Prepare detailed scripts and discussion points for qualitative data collection.
8. Sampling Strategy
Sampling Design: Define the sampling frame, size, and method (e.g., random sampling, stratified sampling) to ensure representation of target demographics.
Participant Recruitment: Plan recruitment strategies to reach and engage the intended participant groups effectively.
9. Data Collection and Analysis Plan
Data Collection: Implement methods for data gathering, ensuring consistency and validity.
Analysis Techniques: Decide on analytical approaches (e.g., statistical
The story of Dr. Ranjit Jagtap's daughters is more than a tale of inherited responsibility; it's a narrative of passion, innovation, and unwavering commitment to a cause greater than oneself. In Poulami and Aditi Jagtap, we see the beautiful continuum of a father's dream and the limitless potential of compassion-driven healthcare.
At Malayali Kerala Spa Ajman we providing the top quality massage services for our customers.
Our massage center prioritizes efficiency to ensure a quality massage experience for our clients at Malayali Kerala Spa Ajman. We offer a convenient appointment system and precise massage services.
Reach us at Villa No 7, Near Ammar Bin Yasir Street Al Rashidiya 2 - Ajman - United Arab Emirates.
Phone : +971 529818279
2. Forward looking statements
This presentation may contain forward-looking statements within the meaning of Section 27A of the U.S. Securities Act
of 1933 and Section 21E of the U.S. Securities Exchange Act of 1934 with respect to the financial condition, results
and business achievements/performance of Genetic Technologies Limited and certain of the plans and objectives of its
management. These statements are statements that are not historical facts.
Words such as “should”, “expects”, “anticipates”, “estimates”, “believes” or similar expressions, as they relate to
Genetic Technologies Limited, are intended to identify forward-looking statements. By their nature, forward-looking
statements involve risk and uncertainty because they reflect Genetic Technologies’ current expectations and
assumptions as to future events and circumstances that may not prove accurate. There is no guarantee that the
expected events, trends or results will actually occur. Any changes in such assumptions or expectations could cause
actual results to differ materially from current expectations.
2
3. Who we are
• Over a decade of R&D surrounding the development of polygenic risk scores
• Developing risk prediction platforms for major oncological, metabolic and degenerative diseases
• Strong scientific leadership under Dr Richard Allman – a pioneer in the development of polygenic risk
scores
• In collaboration with some the world’s most prestigious universities and medical institutes
• Delivering better outcomes at a lower cost to the patient and the medical system
• Supported by a deep, robust IP portfolio
• In 2020 will offer the most comprehensive suite of polygenic risk assessment tests on the market
Genetic Technologies is a leader in genomics
Dual listed on the ASX (GTG) and Nasdaq (GENE) 3
4. In 2003, humanity completed perhaps its most ambitious voyage of exploration when scientists mapped the
human genome – the three-billion-plus pairs of DNA that make us human.
Advances in genomic epidemiology and sequencing technology will influence the way physicians practice
medicine in the 21st century with polygenic predictors used to identify individuals at risk for common chronic
conditions.
4
The human genome
5. Polygenic Risk Score
What is it?
• Most common complex diseases are a result of not one or a few genes, but many acting in concert
• Polygenic Risk Score is a DNA based risk assessment (screening) tool that weighs a person’s odds of
developing common complex diseases by inspecting DNA information spread across the genome
• Genomic and non-genomic factors are considered including lifestyle and family history
• Validated risk stratification method (GWAS)
• Identifies high-risk individuals for earlier and more frequent screening
5Polygenic Risk
Frequency
Average Risk
Relative Risk
X 0.2
Relative Risk
X 5.0
6. Polygenic Risk Score
How do Polygenic Risk Scores differ from genetic testing (e.g. BRCA in breast cancer)?
• Genetic testing only captures hereditary forms of disease (e.g. inherited cancer risk)
• Polygenic Risk Scores capture sporadic (non-inherited) disease, the most common form of all diseases
• It allows for more personalized, precision medicine
6
Polygenic Risk Scores, validated by GWAS (millions of data points),
represent the evolution of disease screening and ultimately prevention.
7. The justification of using Polygenic Risk Score to
inform earlier screening is similar across disease types
7
Breast cancer Colorectal cancer Coronary heart disease
Mavaddat et al. (2015) JNCI Jenkins et al. (2019) Familial Cancer Abraham et al. (2016) Eur Heart J.
8. The unmet need
• Current genetic testing only captures hereditary forms of disease
• Current system is binary - everyone is tested regardless of personal risk status
• Currently system is inefficient with a one-size-fits-all policy based on averages
• Unable to clearly identify high risk groups
• Most testing testing commences at 50 however approximately 20% of diseases occur before 50
• Doesn’t pick up interval cancers - 45% of new cancers which occur between screenings
Until today we haven’t had a product that predicts risk and detects disease
in early stage. Now that we have it, it needs to be integrated into the current
health management system.
8
9. Intellectual property is a core advantage
5 Patents granted in the US
• Patent Nos. 9,051,617; 9,068,229 and 9,702,011 covering three of the core genetic markers included
in the BREVAGenplus® risk assessment test
• Patent No. 7,127,355 offering broad protection re: methods of genetic analysis (the concept of
combining clinical risk assessment with genetic risk factors to improve predictability over clinical risk
assessment alone)
• Patent No. 6,969,589 covering the identification of informative SNPs
GTG has a strong patent portfolio covering the breast cancer risk assessment test
5 Patents granted in China
• Patent Nos. 200680051710.0; 201310524782.4; 201310524916.2 and 201310524765.0
“Markers for Breast Cancer”
• Patent No. 201080033130.5 Methods for Breast Cancer Risk Assessment
5 Patents granted in Hong Kong
• Patent Nos. 09101235.4; 12112875.1; 12112368.5 and 12112874.2 “Markers for Breast
Cancer”
• Patent No. 12109000.5 Methods for Breast Cancer Risk Assessment
7 Patent families pending
• Methods for breast cancer risk
assessment
• Methods for assessing risk of
developing breast cancer
• Improved methods for assessing risk of
developing breast cancer
• Markers for breast cancer
• Methods for genetic analysis
• Methods for genomic analysis
• Methods for assessing risk of
developing colorectal cancer
9
10. Operational overview
Genetic Technologies Limited
Melbourne, Australia
• Technical and corporate support
• CLIA approved laboratory
Phenogen Sciences Inc.
Charlotte, North Carolina, USA
• Clinical and customer support
• Sales and marketing
• Liaison for US collaboration
10
11. Our board
11
Dr. Jerzy “George” Muchnicki
MBBS
Executive Director & Chief Executive Officer (Interim)
Dr. Lindsay Wakefield
MBBS
Non – Executive Director
Mr. Peter Rubinstein
BSc, BEc, LLB
Non – Executive Director
Mr Nick Burrows
B.Com, FAICD, FCA, FGIA, FTIA, F Fin
Non – Executive Director
12. Our vision
• Identify and manage patients who are at high risk of developing major life threatening diseases
• Implement the current protective medical strategies in the best way possible for identified high risk groups
via:
• targeted screening
• lifestyle changes
• chemoprophylaxis and/or surgical intervention as determined by clinicians
• Utilise our powerful predictive/indicative technology as the cornerstone of a preventative medical system
where early detection leads to cost effective and life saving outcomes
12
14. Product range and status
• Our breast and colorectal cancer products are market ready
• T2D and CV tests are in final stages of development
14* Tests are developed and
market launch is scheduled.
Colorectal
Cancer*
Enhanced
Breast Cancer*
Prostate
Cancer
Cardiovascular
Test validation
Type 2 Diabetes
Test validation
Melanoma
Cardiovascular
Market ready 4Q 2020
1Q 2020
2Q 2019
3Q 2020
Type 2 Diabetes
Market ready
15. • Our product development strategy aims to provide coverage of the most significant causes of morbidity
and mortality in the US
• It covers up to 70% of causes of mortality
15
Incidence of underlying causes of mortality in the US
Breast Cancer
Colorectal Cancer
Type 2 Diabetes
Cardiovascular Disease
Other causes
Disease coverage
17. Breast cancer at a glance
• 1 in 8 women will get breast cancer in their lifetime
• Every year approximately 270,000 women will be diagnosed
with breast cancer
• 25% of breast cancers develop before the age of 50 (average
age 62)
• 85% of women have no family history of breast cancer
• 10% have a family history but no pathogenic variants, such
as BRCA
• Only 5% of women with breast cancer have a pathogenic
variant, such as BRCA
17
* Pathogenic variants include those in moderate and high penetration, including but not limited to ATM, BRCA1/2, BRIP1, CDH1, CHEK2, PALB2, PTEN, TP53.
18. Average (asymptomatic) woman at a glance
18
American Cancer Society. Breast Cancer Facts & Figures 2019-2020. Atlanta: American Cancer Society, Inc. 2019.
63
37
Up-to-date mammogram
yes no
Over 1/3 of women
are not screen-
compliant
Nearly half of all
women have a
significant risk factor:
dense breast tissue
43
57
Percentage of women (40+)
with dense breast tissue
dense (BI-RADS c/d) non-dense (BI-RADS a/b)
Kerlikowski et al 2015
• Majority of women do NOT have family history of breast cancer
• Misconception that lack of FH means lower risk of breast cancer thus they tend be less screen-compliant
Haber et al 2012
19. GeneType for Breast Cancer
• GeneType for Breast Cancer (GeneTypeBC) is a first-to-market, clinically validated genetic risk
assessment for non-hereditary (sporadic) breast cancer which represents up to 90% of all breast cancers
• It is the world’s first validated genomic test to accurately predict risk of disease by combining the
information contained in DNA with family history and mammography data to create a powerful new tool in
the battle with breast cancer
19
Simple cheek swab that helps determine a woman’s risk of
developing breast cancer
First test of its kind to be clinically validated to evaluate risk
for sporadic breast cancer
Validated for use in Caucasian, African American and Hispanic
women over age 35
GeneType’s technology covers 95% of women
20. Targeted screening and prevention
More frequent mammograms or MRIs
Selective estrogen receptor modulators (SERMs) or
aromatase inhibitors (AIs)
Weight loss, alcohol consumption, physical activity
GeneType for
Breast Cancer
enables the
targeting of limited
resources to
women who are
most likely to
develop breast
cancer
Screening
Medication
Lifestyle
20
21. Identify at-risk women = Better outcomes
21
• By qualifying high-risk women for risk reducing
medications, you enable clinicians to reduce
breast cancer incidence by upwards of 50%
• Nearly 1 in 4 woman over 40 are at increased
risk of breast cancer based on her 5-year risk
score (>1.66%)
Kerlikowski et al 2015
Risk reduction
• By implementing enhanced surveillance of high-
risk individuals, you enable clinicians to improve
breast cancer detection
• 5-year survival rates dramatically improve when
breast cancer is diagnosed before spreading to
other parts of the body
Screening
https://www.cancer.org/cancer/breast-cancer/understanding-a-breast-cancer-diagnosis/breast-cancer-survival-rates.html
22. Early diagnosis = Less expensive treatment
Stage I…………………….$ 55,000
Stage II……………..…….$103,000
First year
treatment costs
for breast cancer
https://journals.plos.org/plosone/article/figure?id=10.1371/journal.pone.0207993.t001
USD, study based on US patients, 2003-2010
22
Stage III and IV………….$150,000+
23. Wider age and population coverage
23
• GeneType for Breast Cancer tests individuals before age of 35 and covers the African American and
Hispanic population
25. Colorectal cancer at a glance
• 150,000 people are diagnosed with colorectal
cancer every year in US
• 1 in 20 will get colorectal cancer in their lifetime
• Screening begins at 45
• Approximately 10% of colorectal cancer develop
before the age of 50
25
• More than 50% of colorectal cancer are first
identified in late stage
• 69% 5-year survival rate
• Late stage survival
• Over 1/3 of population is not tested
Source: Behavioral Risk Factor Surveillance System, 2012
26. Distribution of lifetime colorectal cancer risk
stratified by polygenic risk and family history
26Jenkins MA, Win AK, Dowty JG, et al: Ability of known susceptibility SNPs to predict colorectal cancer risk for persons with and without a family history. bioRxiv:267666, 2018
• Risk of acquiring the disease as a
high-risk individual is earlier
• Family history is potent in identifying
risk
• Can't look at genomics alone
27. GTG has developed a world-first polygenic risk
test for colorectal cancer
Easy-to-use test solves
the compliance problem
Simple cheek swab test Report sent to your doctor
Clinically actionable results
Informs screening and health
monitoring for those most at risk
Risk stratification enables precision screening and personalised prevention
5-year, 10-year and lifetime risk
27GeneType’s technology covers 95% of colorectal cancer
29. We aim to touch as many lives as possible
through partnerships (network)
Q1 2020 Launch GeneType product
line:
• Consumer initiated
• $249 price point
• Leverage existing clinician networks /
pathology groups
• Further validation with Tgen:
• Utility
• Reimbursement
Partner with genomics market leaders
to integrate Genetic Technologies’
tests into their testing platforms:
• White label/OEM arrangements
• Royalty based
• Shared expense in prosecution of
infringement of Genetic Technologies’
IP
29
Clinics/CITPartnership
30. Partnering as an OEM/white label test
Genetic Technologies is seeking to market its polygenic risk score tests as part of a
wider offering by established genomic testing market leaders
30
Our partner should :
• Be a market leader in CIT or DTC genomics space
• Have a large pool of genomes available for testing using Genetic Technologies’ tests both for R&D and
commercial purposes
• Have a demonstrated interest in expanding their offering from hereditary genomics to Polygenic Risk
Scores
• Have a capability to work with Genetic Technologies to prosecute its IP position
We seek to:
• Grant an OEM license to our tests on a royalty/ profit share basis
• Develop new PRS based tests using partners’ genomics databases
• Exclusively represent our partner in our native market of Australia
31. Consumer Initiated Testing
31
More people are taking control of their health
CIT Will allow Genetic Technologies to offer Polygenic Risk Score tests directly to consumers
• Genetic Technologies is in discussions with a leading provider of CIT services that will Provide outsourced
clinical and logistical backbone to our diagnostics operations
• Anticipate a $249 price point
• Will allow Genetic Technologies to access major markets without a need for a large and expensive sales
force
• We are currently negotiations with US high visibility brand ambassadors to complement this strategy
32. Existing network of clinics
32
• Genetic Technologies plans to leverage existing relationships with its network of clinics
• Strong demand from clinicians familiar with the products and the value proposition of Polygenic Risk
Testing
• Clinics used to offer Genetic Technologies’ previous product, BrevaGen
• 20+ clinics in 12 states
• Clinics span wide breadth of specialties including:
• Primary women’s healthcare
• OB/GYN
• Breast surgical oncology
• High-risk cancer clinics
34. Translational Genomics Research Institute
(TGen): Collaborative Network
Collaborations
with
427academic, medical,
and industry
partners worldwide
(28 countries &
U.S. territories)
Spun out
16
companies
Other:
Government: Local,
State (ADHS, CDPH), Federal (NIH,
FDA, CDC), Philanthropy, Patients
Health Care Partners:
Community hospitals, health care
systems, and oncology networks; >1000
physicians (Primary Care, Specialists,
Medical Oncology, Surgeons)
Background
- Est. 2002
- Non-profit (501c3)
- Patient-focused clinical & basic research
- Pioneers in precision genomic medicine
- Expertise includes: Clinicians, laboratory
and computer scientists, data analysts,
and business development
- Joined City of Hope in Nov. 2016
Highlights
- Performing personalized cancer treatment
since circa 2008
- 1st polygenic risk score paper
published in 2008 (NEJM)
- Performing whole genome sequencing to
inform cancer therapy since circa 2010
- 1st precision medicine trial for children’s
cancer published in 2014
- Regularly conduct 1st in human clinical
trials
- Supercomputer built specifically for
genomic applications
- Developer and early adopter of paradigm
shifting technologies
Areas of Disease Focus
- Oncology
- Neurology
- Rare Childhood Disorders
- Diabetes
- Infectious Disease
Research Specialties
- Population Genetics
- Cancer Prevention and Early Detection
- Rare (Childhood) Disease
- Circulating Biomarkers
- Quantitative Medicine
- Infectious Disease
- Tumor Profiling/Drug Selection
- Clinical Trials
Basic Computing to High
Performance Computing
Basic Data Analysis to Quantitative
Medicine
www.tgen.org 34
35. Collaboration is a key market advantage
The University of Melbourne
• Australia’s peak research-intensive institution, ranked 32nd globally
Our collaboration with The University of Melbourne was awarded an NHMRC grant
• Research investigation to assess the improvement in breast cancer risk prediction using polygenic risk
• Led by Professor John Hopper
• National Health and Medical Research Council is Australia’s peak funding body for cutting-edge research
This work has established GTG as a global leader in polygenic risk
research and development
Professor John Hopper
• PhD in Mathematical Statistics
• NHMRC Senior Principal Research Fellow
• Director (Research) of the Centre for Epidemiology and Biostatistics in the School of Population
Global Health at The University of Melbourne
• Published more than 700 papers
35
36. Research into clinical applications
GTG has an agreement in place with Memorial Sloan Kettering (MSK) and University of Cambridge
• The research is led by Mark E. Robson, MD, Chief of Breast Medicine Service, Memorial Sloan Kettering
• MSK is the world’s oldest and largest cancer treatment and research institution
• Memorial Sloan Kettering was ranked second among hospitals specializing in cancer treatment in the US
• The University of Cambridge’s UK Institute is a world leading cancer biotech center
Genetic Technologies partners with world-leading research hospitals to
develop the clinical use of polygenic risk scores in treatment decisions 36
37. Other key partnerships
Ohio State University (Columbus, Ohio)
• Research collaboration exploring polygenic risk as a means to more informed decision-making for
women with BRCA mutations
• Led by Amanda Toland, Director of Clinical Genetics and a leader in the field of breast cancer risk
assessment
Nurses’ Health Study
• Harvard University prospective study of the risk factors for major chronic diseases in women
• Collaborating with principle investigators to validate new risk models for breast cancer
37
38. Genetic Technologies’ snapshot
38
• Current market cap as of 9/01/2020: $27.9M
• Dual listed ASX/NASDAQ
• App. No. Shares on issue: 4,000,000,000 (ADR @ 600:1)
• $US 3M cash as of 31 December 2019
• Company funded out to Q1 2021 based on current business plan
39. An exciting year ahead for Genetic Technologies
• GeneType for Breast Cancer and GeneType for Colorectal cancer market ready
• Start US Sales and marketing through existing clinician network
• Start of clinical utility study in conjunction with Tgen
Upcoming catalysts aim to increase revenues and generate shareholder value
39
• Launching CIT operations
• Complete work on type-2 diabetes risk test
• Complete work cardiovascular risk test
• Closing of OEM agreement in the US
• Introduce 2 additional tests for a total of 4 tests
• Expansion of Tgen collaboration based on clinical utility results
Q1 2020
Q2 2020
H2 2020
40. Thank you
Dr George Muchnicki
Executive Director and Interim CEO
george.muchnicki@gtglabs.com
www.gtglabs.com
40